Effects of plant stanol or sterol-enriched diets on lipid profiles in patients treated with statins: systematic review and meta-analysis

Shufen Han¹, Jun Jiao¹, Jiaying Xu², Diane Zimmermann³, Lucas Actis-Goreta³,⁴, Lei Guan⁵, Youyou Zhao⁵ & Liqiang Qin¹

Efficacy and safety data from trials with suitable endpoints have shown that non-statin medication in combination with a statin is a potential strategy to further reduce cardiovascular events. We aimed to evaluate the overall effect of stanol- or sterol-enriched diets on serum lipid profiles in patients treated with statins by conducting a meta-analysis of randomized controlled trials (RCTs). We used the PubMed, Cochrane library and ClinicalTrials.gov databases to search for literature published up to December 2015. Trials were included in the analysis if they were RCTs evaluating the effect of plant stanols or sterols in patients under statin therapy that reported corresponding data on serum lipid profiles. We included 15 RCTs involving a total of 500 participants. Stanol- or sterol-enriched diets in combination with statins, compared with statins alone, produced significant reductions in total cholesterol of 0.30 mmol/L (95% CI −0.36 to −0.25) and low-density lipoprotein (LDL) cholesterol of 0.30 mmol/L (95% CI −0.35 to −0.25), but not in high-density lipoprotein cholesterol or triglycerides. These results persisted in the subgroup analysis. Our meta-analysis provides further evidence that stanol- or sterol-enriched diets additionally lower total cholesterol and LDL-cholesterol levels in patients treated with statins beyond that achieved by statins alone.

Cardiovascular disease (CVD) is the leading cause of death among chronic diseases worldwide. Elevated levels of total cholesterol and low-density lipoprotein (LDL) cholesterol are important risk factors for developing CVD¹. Extensive evidence suggests that lower levels of total and LDL-cholesterol are associated with decreased ischemic heart disease mortality². Given these findings, the 2013 guidelines of the American College of Cardiology and the American Heart Association (ACC-AHA) for the treatment of cholesterol abandoned LDL targets and advocated “the lower the better” strategy¹. In view of the robust evidence³, statin therapy, through inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase⁴, is emphasized in current US guidelines as the main treatment to reduce LDL-cholesterol. However, some patients do not reach target lipid values recommended by the National Cholesterol Education Program (NCEP) with statin monotherapy, and a long-term treatment with statin is always not been accepted in many patients due to its side effects.

Phytosterols, steroid compounds including plant stanols and sterols, present a similar structure to that of cholesterol. They are thought to decrease plasma cholesterol concentration by reducing intestinal absorption of cholesterol, upregulating hepatic expression of the LDL receptors, and decreasing production of endogenous LDL-cholesterol⁵. Studies have suggested that phytosterols may confer an additional benefit in lowering of serum lipid concentrations in patients treated with statins⁶,⁷. These compounds have therefore been

¹Department of Nutrition and Food Hygiene, Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, School of Public Health, Soochow University, Suzhou, China. ²Key Laboratory of Radiation Biology, School of Radiation Medicine and Protection, Soochow University, Suzhou, China. ³Nestlé Research Centre Lausanne, Lausanne, Switzerland. ⁴Nestlé Research Centre Singapore, Singapore. ⁵Nestlé Research Centre Beijing, Beijing, China. Correspondence and requests for materials should be addressed to Y.Z. (email: Youyou.Zhao@rd.nestle.com) or L.Q. (email: qinliqiang@suda.edu.cn)
recommended for patients who do not reach statin treatment targets for LDL-cholesterol and in management of mild hypercholesterolemia\(^9,10\).

Since the 1950s, numerous studies have observed the effect of phytosterols on LDL-cholesterol and several meta-analyses have evaluated their effect on serum lipid profiles\(^1,11–13\). Such analyses have concluded that circulating LDL-cholesterol concentration decreases with increasing phytosterol content. For example, Ras et al. found that LDL-cholesterol decreased as much as 12% as phytosterol administration increased up to approximately 3 g/d\(^13\). Similarly, a mathematical modeling approach predicted that a sterol or stanol intake of 2 g/d in combination with statins reduces LDL-cholesterol by an additional 8–9%, an effect similar to that achieved by doubling the dose of statins\(^14\).

Recent trials have focused on the combined effects of phytosterols and statins on lipid profiles in hypercholesterolemic patients and other patients treated with statins\(^7,15\). In a meta-analysis published in 2009, Scholle et al. evaluated eight randomized controlled trials (RCTs) involving hypercholesterolemic patients; they found that plant sterols or stanols combined with statins decreased the total cholesterol and LDL-cholesterol by 0.36 mmol/L and 0.34 mmol/L, respectively\(^16\). A recent retrospective cohort study analyzed data from questionnaire responses from 3829 subjects, 43 of whom used combination treatment with statins and phytosterols (in the form of sterol- or stanol-enriched margarine) at the 5-year follow-up. Recommended margarine intake was 27 g/d. Cholesterol was reduced dose-dependently with increasing phytosterol intake (decrease of \(−0.0094\) mmol/L for each gram of enriched margarine), with a significant reduction of 0.32 mmol/L in subjects with an intake of \(≥20\) g/d\(^17\).

An up-to-date and timely meta-analysis is important for several reasons. Previous meta-analyses have only focused on hypercholesterolemic patients, without performing comprehensive research. Since then, a large number of studies have become available, allowing the addition of subgroup analyses for important characteristics of subjects and design. We therefore performed a meta-analysis ranging from the earliest to the most recent RCTs to examine whether combined treatment of plant stanols or sterols together with statins positively affects lipid profiles compared with statins alone in treated patients.

Results

Study characteristics. After systematic review of the literature, 14 studies, including 15 trials, satisfied the inclusion criteria for this meta-analysis (Fig. 1)\(^7,8,15,18–28\). The characteristics of the selected trials are presented in Tables 1 and 2. These studies were published between 1996 and 2015, and performed in the USA (\(n = 3\)), Netherlands (\(n = 3\)), Finland (\(n = 2\)), Spain (\(n = 1\)), Australia (\(n = 1\)), UK (\(n = 1\)), and Germany (\(n = 1\)), Portugal (\(n = 1\)), and Brazil (\(n = 1\)). Nine trials had a parallel design, and the remaining trials had a crossover design. Nine trials were double blinded, and the remaining trials were single blinded (\(n = 1\)), open-label (\(n = 3\)), or gave no information on blinding (\(n = 2\)). The intervention duration lasted from 4 to 85 weeks with a median of 6 weeks.

With regard to participants, twelve studies enrolled men and women, and two included men only. The number of participants in each trial varied from 8 to 141, with a sum of 382 in the parallel trials and 118 in the crossover trials. The participants in nine studies suffered from hypercholesterolemia, and the other studies involved patients with dyslipidemias, metabolic syndrome, type 1 diabetes mellitus, and impaired retinal vasculature. Not all studies provided comprehensive information of lipid index that we needed; one study did not present triglyceride data\(^15\) and one lacked LDL-cholesterol index\(^8\).

Phytosterol intake differed in these studies. Ten studies used margarine containing plant stanol or sterol ester, one study used a low-fat plant sterol-enriched fermented milk, one study administered beta-sitosterol, one study used a dried stanol/lecithin complex in tablet form, and one study received capsules containing plant sterols. Two
Table 1. Characteristic of the trials and participants in this meta-analysis. X: cross-over; P: parallel; SB: single blind; DB: double blind; B: blind; O: open-label; NR: not reported. *For parallel design, sample size is intervention group/control group.

| First author | year | Country | Study design | Sample size | Male (%) | Age (year) | BMI (kg/m²) | Duration (wk) | Baseline (mmol/L) |
|--------------|------|---------|--------------|-------------|----------|------------|-------------|--------------|------------------|
| Malina       | 2015 | Brazil  | X, O         | 35          | 23       | 62         | 30.2        | 4            | TC: 2.60, HDL-C: 1.33, LDL-C: 1.50 |
| Andrade      | 2015 | Portugal| X, O         | 35          | 11       | 81         | 29.9        | 6            | TC: 4.31, HDL-C: 2.60, LDL-C: 1.33 |
| Hallikainen  | 2011 | Finland | P, DB        | 12/12       | 50       | 64         | 18–70       | 27.2         | TC: 5.18, HDL-C: 3.21, LDL-C: 1.30 |
| Kelly        | 2011 | Netherlands | P, DB | 8/11       | 58       | 61         | 25.8        | 85           | TC: 5.38, HDL-C: 3.29, LDL-C: NR |
| Platz        | 2009 | Netherlands | P         | 8/10       | 61       | 46         | 60.6        | 29.4         | TC: 5.56, HDL-C: 3.41, LDL-C: 1.38 |
| De Jong      | 2008 | Portugal | P, DB        | 15/11       | 46       | 58.3       | 58.2        | 26.8         | TC: 5.29, HDL-C: 3.34, LDL-C: 1.41 |
| Fuentes      | 2008 | Spain   | X, DB        | 30          | 50       | 42         | 26.5        | 4            | TC: 5.95, HDL-C: 4.00, LDL-C: 1.38 |
| Fuentes      | 2008 | Spain   | X, DB        | 30          | 50       | 42         | 26.5        | 4            | TC: 5.95, HDL-C: 4.00, LDL-C: 1.38 |
| Goldberg     | 2006 | USA     | P, DB        | 13/13       | 35       | 59.5       | 59.5        | 27.2         | TC: 5.36, HDL-C: 3.25, LDL-C: 1.32 |
| Cabezas      | 2006 | Netherlands | P, SB | 11/9       | 40       | 48.4       | 26.2        | 6            | TC: 6.88, HDL-C: 4.84, LDL-C: 1.14 |
| Cater        | 2005 | USA     | X, DB        | 10          | 100      | 66         | 29.5        | 8            | TC: 6.01, HDL-C: 3.85, LDL-C: 1.38 |
| Simons       | 2002 | Australia | P, DB      | 37/38       | 47       | 60         | 26.2        | 4            | TC: 5.74, HDL-C: 5.25, LDL-C: 1.40 |
| Blair        | 2000 | USA     | P, DB        | 69/72       | 60       | 56         | 29.0        | 8            | TC: 8.01, HDL-C: 3.85, LDL-C: 1.77 |
| Gyling       | 1996 | Finland | X, B         | 8           | 100      | 60.2       | 26.6        | 7            | TC: 7.69, HDL-C: 5.70, LDL-C: 1.31 |
| Richter      | 1996 | Germany | P, O         | 15/15       | 53       | 45.5       | 26.3        | 12           | TC: 6.89, HDL-C: 3.48, LDL-C: 1.59 |

Effect of phytosterols combined with statins on lipid profiles. The net changes and the corresponding 95% CIs for total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides are presented in Fig. 2. Compared with statins alone, combined treatment presented an average net change ranging from −0.61 mmol/L to −0.15 mmol/L for total cholesterol (Fig. 2A), with 6 of 15 trials reaching statistical significance. Similarly, the net change for LDL-cholesterol ranged from −0.55 mmol/L to −0.13 mmol/L (Fig. 2B), with 8 of 14 trials reaching statistical significance. Since no statistical heterogeneity in total cholesterol, LDL-cholesterol, HDL-cholesterol and triglyceride analyses (P = 0 for all), the fixed-effect model was used. After meta-analysis, with the overall effect size of combined treatment was −0.30 mmol/L (95% CI: −0.36 to −0.25) and −0.30 mmol/L (95% CI: −0.35 to −0.25) for total cholesterol and LDL-cholesterol, respectively. And the overall effect size of combined treatment was 0 (95% CI: −0.01 to 0.02) for HDL-cholesterol (Fig. 2C) and −0.04 mmol/L (95% CI: −0.09 to 0.01) for triglycerides (Fig. 2D).

Subgroup and sensitivity analyses. Tables 3 and 4 show the results from subgroup analyses. According to subgroup analyses (Table 3), this reduction on total cholesterol was somewhat pronounced in participants with high baseline values and a low phytosterol dose of less than 3 g. This reduction on LDL-cholesterol was somewhat pronounced in participants with high baseline values, long treatment duration, and a high phytosterol dose of more than 3 g. However, the differences among all subgroups did not reach the statistical significance. The results of subgroup analyses did not reveal the effects of combined treatment on HDL-cholesterol and triglycerides (Table 4). A sensitivity analysis was conducted by omitting one trial each in turn to yield a narrow range with minimal changes in the levels of total cholesterol (from −0.30 mmol/L to −0.31 mmol/L), LDL-cholesterol (from −0.31 mmol/L to −0.32 mmol/L) and HDL-cholesterol (from −0.31 mmol/L to −0.32 mmol/L). However, the overall effect size on triglycerides was −0.06 mmol/L (95% CI: −0.13 to 0.00) after excluding the trial by Goldberg et al. and this finding presents a different conclusion from the results of the total analysis.

Two studies, those of Kelly et al. and De Jong et al. used both plant stanols and sterols in combination with statins. In the sensitivity analyses conducted on these studies, the selected plant sterols combined with statin treatment presented an overall effect size of −0.30 mmol/L (95% CI: −0.36 to −0.25) for total cholesterol, −0.30 mmol/L (95% CI: −0.34 to −0.25) for LDL-cholesterol, 0 mmol/L (95% CI: −0.01 to 0.02) for HDL-cholesterol and −0.04 mmol/L (95% CI: −0.09 to 0.01) for triglycerides. The results from these two studies were consistent when plant stanols were used in the analyses.

Meta-regression analyses. To minimize the likelihood of false-positive results, we carefully selected a small number of covariates, including baseline lipid level, intervention duration, and phytosterol dose. In the meta-regression analysis, none of these three covariates significantly influenced the overall effect size for total cholesterol (P = 0.89, 0.17, 0.95), LDL-cholesterol (P = 0.48, 0.22, 0.50), HDL-cholesterol (P = 0.43, 0.13, 0.66) and triglycerides (P = 0.68, 0.38, 0.88).

studies combined statin therapy with plant stanols and plant sterols, respectively, and one study included two trials with different cholesterol concentrations in a sitostanol-enriched diet. Phytosterol dosage in the intervention group varied from 1.8 g/d to 6 g/d, with a median of 2.5 g/d. Most of the control group received no or less than 0.5 g/d phytosterols.
| First author | Statin dose | Plant sterol/stanol | Intervention group | Control group dose | Diet composition |
|--------------|-------------|---------------------|-------------------|-------------------|-----------------|
| Malina       | Atorvastatin (10 mg/d) for 4 weeks run-in period, and then stable doses of atorvastatin (40 mg/d) | Plant sterol, 2.0 g/d | No | No oral plant sterols | Reinforcing lifestyle changes |
| Andrade      | Stable statin therapy | Plant sterol, 2.0 g/d | No | Free plant sterols | Maintaining their usual dietary pattern as well as physical activity |
| Hallikainen  | Stable doses of atorvastatin, rosuvastatin or simvastatin | Plant stanols, 3.0 g/d | Yes | about 0.1 g/d plant sterols | Vegetable oil-based spread provided by Raisio Nutrition Ltd. 64% fat for intervention group, and 49% fat for control group |
| Kelly        | Stably with statin | Plant sterols, 2.5 g/d | Plant stanols, 2.5 g/d | Yes | Free plant stanols | Keeping the normal diet and physical exercise level, and smoking and alcohol consumption |
| Plat         | A low-dose OTC statin (10 mg simvastatin) | Plant stanol, 2 g/d | Yes | No oral plant sterols | No change in habitual diet other than low-fat yogurt drink (234 kJ/100 mL) |
| De Jong      | Stable doses of atorvastatin, simvastatin or pravastatin | Plant sterols, 2.5 g/d | Plant stanols, 2.5 g/d | Yes | No added plant stanol | No change in habitual diet other than margarine use |
| Fuentes      | Stable doses of atorvastatin or simvastatin (40 mg/d) for at least 8 weeks prior | Sitosterol, 2.5 g/d | No | <0.5 g/d plant sterol from control diet | 280–300 mg/d cholesterol, <30% fat, <10% saturated fat, 6% PUFA, 12% MUFA |
| Fuentes      | Stable doses of atorvastatin or simvastatin (40 mg/d) for at least 8 weeks prior | Sitosterol, 2.5 g/d | No | <0.5 g/d plant sterol from control diet | 150mg/d cholesterol, <30% fat, <10% saturated fat, 6% PUFA, 12% MUFA |
| Goldberg     | Stable statin dose for at least 3 months prior | Plant stanols, 1.8 g/d | No | Placebo tablet containing starch | American Heart Association Heart Healthy Diet |
| Cabezas      | Stable doses of atorvastatin or simvastatin (80 mg/d) for at least 6 months prior | Plant stanols, 3 g/d | No | No adding plant stanol | Dietary education only |
| Cater        | Stable doses of simvastatin or atorvastatin for ≥2 months prior | Plant stanol, 3 g/d | Yes | No adding plant stanol | A diet low in saturated fat (<10% daily calories) and cholesterol (<300 mg/d) |
| Simons       | Cerivastatin (400 μg/d) | Plant sterol, 2 g/d | Yes | Virtually no serol | American Heart Association Step 1 diet |
| Blair        | Stable doses of atorvastatin, pravastatin, simvastatin or lovastatin for at least 90 days prior | Plant stanol, 3 g/d | Yes | No adding plant stanol | No change in habitual diet other than margarine use for intervention group. 24 g/d of matching canola oil-based placebo margarine with average fat content of 18 g for control group |
| Gylling      | Pravastatin (40 mg/d) | Sitosterol, 3 g/d | Yes | 50.2 mg/d campesterol and 69.1 mg/d sitosterol | No change in habitual diet other than margarine use |
| Richter      | Maximally tolerated dose of lovastatin (56.5 ± 25.0 mg/d) | β-sitosterol, 6 g/d | No | No oral plant sterol | A cholesterol-lowering diet as recommended by the European Atherosclerosis Society |

Table 2. Statin dose, plant sterol/stanol dose, and diet composition of the trials and participants in this meta-analysis.

**Publication bias.** Visual inspection of Begg funnel plot show no asymmetry in total cholesterol, LDL-cholesterol and HDL-cholesterol and some asymmetry in triglycerides (Data not shown). Further quantitative analysis showed that there was no publication bias for total cholesterol, LDL-cholesterol and HDL-cholesterol from the Begg funnel plot (P = 0.59, 0.78 and 0.05, respectively) or Egger regression test (P = 0.48, 0.88 and 0.12, respectively). However, the results for triglycerides from the Begg funnel plot (P = 0.03) and Egger regression test (P = 0.02) showed significant publication bias.

**Discussion**

Our meta-analysis of 15 RCTs showed that combination treatment with statins together with phytosterols significantly decreased the levels of total cholesterol by 0.30 mmol/L and LDL-cholesterol by 0.30 mmol/L, compared with statins alone. However, combined treatment had no effect on HDL-cholesterol and triglyceride levels.

The findings have potential public health implications. Although some patients who received the combined treatment did not reach the LDL-cholesterol targets (<2.0 mmol/L), a reduction of 0.026 mmol/L (1 mg/dL) in LDL-cholesterol would be expected to decrease the relative risk for cardiovascular diseases by approximately 1%30. High cholesterol is a major risk factor for CVD, which can have devastating consequences and place a high potential burden of disease on patients and healthcare systems. Therefore, even a slight reduction in LDL-cholesterol may contribute to the clinical benefit of supplementary plant stanol or sterol intake. Recent strategies for cholesterol reduction have called for additional therapies beyond statins, since some patients are intolerant or do not respond adequately to statins alone31. Some studies have further suggested that plant stanols could be used as primary and secondary prevention with low statin doses to avoid possible adverse effects32. This
may be due, in part, to the different mechanism of action between statins, which inhibit HMG-CoA reductase, and phytosterols, which may have a complementary effect by inhibiting cholesterol absorption.

The nutritional interest derives from the fact that phytosterols have a similar structure to cholesterol, and have the capacity to lower plasma cholesterol and LDL-cholesterol\(^3^3\). Phytosterols are specific inhibitors of intestinal cholesterol absorption and are thought to compete with cholesterol for solubilization into mixed micelles\(^9\), and ultimately result in an increased fecal output of cholesterol\(^3^4,3^5\). A recently published landmark study, IMPROVE-IT, is the first clinical study to show a reduction in the rate of cardiovascular events by addition of a non-statin lipid-modifying agent (ezetimibe) to statin therapy\(^3^6\). In this study, LDL-cholesterol level was 1.4 mmol/L in the simvastatin-ezetimibe group, as compared with 1.8 mmol/L in the simvastatin- monotherapy group; the effect size for LDL-cholesterol (−0.4 mmol/L) was lightly pronounced than that in our meta-analysis (−0.3 mmol/L). However, it should be interpreted with caution because of the differences between phytosterols and ezetimibe in molecular structure.

In our investigation, the observed reductions in total and LDL-cholesterol persisted through subgroup analysis. This suggests that the beneficial effects of combined treatment are probably independent and not affected by these characteristics. In addition, meta-regression analyses showed that the selected covariates, including baseline lipid level, intervention duration, and phytosterol dose, did not affect the results. Nevertheless, lifestyle modification should be noted. Although the difference after diet modification did not reach the statistical significance in the subgroup analysis, it should be interpreted with caution because of the differences between phytosterols and ezetimibe in molecular structure.

In our investigation, the observed reductions in total and LDL-cholesterol persisted through subgroup analysis. This suggests that the beneficial effects of combined treatment are probably independent and not affected by these characteristics. In addition, meta-regression analyses showed that the selected covariates, including baseline lipid level, intervention duration, and phytosterol dose, did not affect the results. Nevertheless, lifestyle modification should be noted. Although the difference after diet modification did not reach the statistical significance in the subgroup analysis, lifestyle modification is considered the cornerstone of reducing CVD risk\(^3^7\), and one of the key recommendations is the consumption of a healthy diet\(^3^8\). It remains unclear whether the effects of phytosterols on lipid profiles are dependent on lifestyle modification through decreasing dietary fat and cholesterol levels.

Although this meta-analysis was not primarily restricted by heterogeneity across the included studies, which affirmed the interpretation of our findings, certain characteristics distinguish this study from the others included in this analysis. For example, older men were selected as participants, and the baseline of serum lipid profiles were not reported. Furthermore, the overall effect size on triglycerides became significant after excluding the study by Goldberg et al.\(^2^5\). Some factors should be considered to explain this result. Firstly, this trial used a dried stanol/
we conducted a systematic literature search using the PubMed, Cochrane library and the ClinicalTrials.gov databases up to December 2015 using the following sets of search terms: (1) sterol, stanol, sitostanol, phytosterol, phytostanol, beta-sitostanol, beta-sitostanol, stanol ester, sterol ester and fluvastatin, cerivastatin, atorvastatin, simvastatin, pravastatin, lovastatin, rosuvastatin, statin, HMG-CoA reductase inhibitor, in combination with (2) lipids, cholesterol, high-density lipoproteins (HDL), low-density lipoproteins (LDL), and triglycerides; searches were performed with no restrictions. Only published

## Materials and Methods

### Data sources and study selection.
We conducted a systematic literature search using the PubMed, Cochrane library and the ClinicalTrials.gov databases up to December 2015 using the following sets of search terms: (1) sterol, stanol, sitostanol, phytosterol, phytostanol, beta-sitostanol, beta-sitostanol, stanol ester, sterol ester and fluvastatin, cerivastatin, atorvastatin, simvastatin, pravastatin, lovastatin, rosuvastatin, statin, HMG-CoA reductase inhibitor, in combination with (2) lipids, cholesterol, high-density lipoproteins (HDL), low-density lipoproteins (LDL), and triglycerides; searches were performed with no restrictions. Only published

| Group          | Study design | Duration | Intervention | Diet modification | Stanol or sterol dose | Baseline | Net change (95% CI) | P-heterogeneity | P (%) |
|----------------|--------------|----------|--------------|-------------------|-----------------------|----------|---------------------|-----------------|-------|
| Total cholesterol |              |          |              |                   |                       |          | −0.30 (−0.36, −0.25) | 0.953            | 0     |
| Group          | Study design | Duration | Intervention | Diet modification | Stanol or sterol dose | Baseline | Net change (95% CI) | P-heterogeneity | P (%) |
| Baseline |              |          |              |                   |                       |          | −0.30 (−0.35, −0.25) | 0.958            | 0     |
| ≥6 mmol/L     | cross-over   | ≥7 wk    | sterol only  | yes               | ≥3 g                  | 6         | −0.30 (−0.35, −0.25) | 0.953            | 0     |
| <6 mmol/L     | parallel     | <6 wk    | stanol only  | no                | <3 g                  | 9         | −0.30 (−0.35, −0.25) | 0.958            | 0     |
| LDL-cholesterol |              |          |              |                   |                       |          | −0.30 (−0.35, −0.25) | 0.958            | 0     |
| Group          | Study design | Duration | Intervention | Diet modification | Stanol or sterol dose | Baseline | Net change (95% CI) | P-heterogeneity | P (%) |
| Baseline |              |          |              |                   |                       |          | −0.30 (−0.35, −0.25) | 0.953            | 0     |
| ≥3.5 mmol/L   | cross-over   | ≥7 wk    | sterol only  | yes               | ≥3 g                  | 6         | −0.30 (−0.35, −0.25) | 0.958            | 0     |
| <3.5 mmol/L   | parallel     | <6 wk    | stanol only  | no                | <3 g                  | 9         | −0.30 (−0.35, −0.25) | 0.958            | 0     |

Table 3. Results of subgroup analyses according to trial and participant characteristics for total cholesterol and LDL-cholesterol.

There are several limitations to this meta-analysis. Firstly, the sample size of individual trials was relatively small, thereby restricting the capacity of randomization to minimize the potential influences of confounding factors. Secondly, characteristics were not balanced between the treatment and control groups in some trials. For example, in one trial, more participants in the combined treatment group had a higher serum baseline of total cholesterol and LDL-cholesterol. Thirdly, the validity of our meta-analysis is dependent on the quality of the individual studies, and there were some issues with some of the trials in this regard. Specifically, allocation concealment, quality of randomization, and details of withdrawals were not always reported. Fourthly, the dose of plant sterols or plant stanols in most of the trials was 2.5 or 3 g/day, so the present meta-analysis was performed on the dose-response effect on TC and LDL-cholesterol. Finally, as with any meta-analysis, publication bias may affect the results. Although formal statistical tests did not detect evidence of publication bias, except for triglyceride results, the power of this analysis is limited because of the relatively low number of studies.

In conclusion, this meta-analysis provides evidence that phytosterol supplementation in patients treated with statins additionally decreases the levels of total cholesterol and LDL-cholesterol beyond that conferred by statins alone. Although it has been suggested that there was a lack of randomised data of the impact of phytosterol on CVD prevention, enhanced consumption of phytosterol may be considered as an adjunct of statin for attainment of LDL-C goals as a function of overall CV risk can be enhanced. Well-designed RCTs must be conducted to confirm the cholesterol-lowering effect of phytosterol supplementation in patients treated with statins on CVD outcomes.
#### Table 4. Results of subgroup analyses according to trial and participant characteristics for HDL-cholesterol and triglycerides.

| Group                  | No | Net change (95% CI) | P-heterogeneity | I² (%) |
|------------------------|----|---------------------|-----------------|--------|
| HDL-cholesterol        |    |                     |                 |        |
| Baseline               |    |                     |                 |        |
| ≥1.35 mmol/L           | 6  | 0.01 (−0.04, 0.06)  | 0.572           | 0      |
| <1.35 mmol/L           | 7  | 0.00 (−0.02, 0.02)  | 0.753           | 0      |
| Duration               |    |                     |                 |        |
| ≥7 wk                  | 7  | 0.04 (−0.01, 0.09)  | 0.460 | 0      |
| <6 wk                  | 8  | 0.00 (−0.02, 0.02)  | 1.000 | 0      |
| Stanol or sterol dose  |    |                     |                 |        |
| ≥3 g                   | 6  | 0.00 (−0.02, 0.02)  | 0.687 | 0      |
| <3 g                   | 9  | 0.03 (−0.02, −0.09) | 0.859 | 0      |
| Diet modification      |    |                     |                 |        |
| yes                    | 8  | 0.00 (−0.02, 0.02)  | 0.876 | 0      |
| no                     | 7  | 0.02 (−0.03, 0.07)  | 0.617 | 0      |
| Intervention           |    |                     |                 |        |
| sterol only            | 8  | 0.04 (−0.02, 0.09)  | 0.776 | 0      |
| stanol only            | 9  | 0.00 (−0.01, 0.02)  | 0.631 | 0      |
| Study design           |    |                     |                 |        |
| parallel               | 9  | 0.00 (−0.02, 0.02)  | 0.503 | 0      |
| cross-over             | 6  | 0.02 (−0.04, 0.07)  | 0.981 | 0      |
| Triglycerides          |    |                     |                 |        |
| Baseline               |    |                     |                 |        |
| ≥1.7 mmol/L            | 5  | −0.02 (−0.10, 0.07) | 0.610 | 0      |
| <1.7 mmol/L            | 7  | −0.07 (−0.15, 0.02) | 0.842 | 0      |
| Duration               |    |                     |                 |        |
| ≥7 wk                  | 6  | −0.07 (−0.16, 0.02) | 0.876 | 0      |
| <6 wk                  | 8  | −0.02 (−0.09, 0.04) | 0.814 | 0      |
| Stanol or sterol dose  |    |                     |                 |        |
| ≥3 g                   | 6  | −0.03 (−0.09, 0.04) | 0.796 | 0      |
| <3 g                   | 8  | −0.07 (−0.16, 0.03) | 0.852 | 0      |
| Diet modification      |    |                     |                 |        |
| yes                    | 8  | −0.02 (−0.09, 0.05) | 0.812 | 0      |
| no                     | 6  | −0.07 (−0.15, 0.02) | 0.892 | 0      |
| Intervention           |    |                     |                 |        |
| sterol only            | 7  | −0.06 (−0.17, 0.04) | 0.799 | 0      |
| stanol only            | 8  | −0.04 (−0.10, 0.02) | 0.824 | 0      |
| Study design           |    |                     |                 |        |
| parallel               | 8  | −0.04 (−0.11, 0.03) | 0.689 | 0      |
| cross-over             | 6  | −0.04 (−0.12, 0.05) | 0.930 | 0      |

For parallel trials, net changes in each index were calculated as the difference between final and baseline values in intervention and control groups, respectively. For crossover trials, net changes were calculated as the differences in mean values at the end between the intervention and control groups. Studies with no reported SD had their values imputed from standard errors, confidence interval (CI) or P values using a standard formula for the analysis. The homogeneity of the effect size among studies was tested using the Cochran Q test at a significance level of P < 0.10. We also calculated the I² statistic, a quantitative measure of inconsistency across studies. An I² value > 50% was considered to indicate substantial heterogeneity across trials. In the presence of significant heterogeneity, we reported the results of subgroup analyses according to trial and participant characteristics for HDL-cholesterol and triglycerides.
heterogeneity, the random-effect model was used to calculate the overall effect size; otherwise, the fixed-effect model was acceptable. Pre-specified subgroup analysis was conducted to figure out the possible effects of study designs and participant characteristics on overall effect size. A sensitivity analysis was conducted to investigate the influence of a single study on overall effect estimate by omitting each study while pooling the results from the remainder. Additional sensitivity analyses were conducted by using data from plant sterols instead of plant stanols when both phytosterols were used in combination treatment. Furthermore, we performed meta-regression analyses to explore possible sources of heterogeneity across studies. Potential publication bias was assessed using Begg’s funnel plots and the Egger regression test. All analyses were performed using STATA version 11.0 (StataCorp., College Station, TX, USA). P < 0.05 was considered statistically significant, except where otherwise specified.

References
1. Steinberg, D. & Gotto, A. M. Jr. Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. Jama 282, 2043–2050 (1999).
2. Prospective Studies Collaboration et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 367, 1829–1839 (2001).
3. Stone, N. J. et al. 2013 ACC/AHA guideline for the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129, S1–S62 (2014).
4. Cholesterol Treatment Trials’ (C TT) Collaboration et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681 (2010).
5. Grundy, S. M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med 319, 24–33 (1998).
6. de Jong, A., Plat, J. & Mensink, R. P. Metabolic effects of plant sterols and stanols. J. Nutr. Biochem 14, 362–369 (2003).
7. Hallikainen, M. et al. Plant stanol esters lower LDL cholesterol level in statin-treated subjects with type 1 diabetes by interfering the absorption and synthesis of cholesterol. Atherosclerosis 217, 473–478 (2011).
8. Plat, J. et al. A plant stanol yogurt drink alone or combined with a low-dose statin lowers serum triglyceride and non-HDL cholesterol in metabolic syndrome patients. J. Nutr 139, 1143–1149 (2009).
9. Katam, M. B. et al. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin. Proc 78, 965–978 (2003).
10. Cylling, H. et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 232, 346–360 (2014).
11. Demonty, I. et al. Continuous dose-response relationship of the LDL-cholesterol-lowering effect of plant sterol intake. J. Nutr 139, 271–284 (2009).
12. Musa-Veloso, K., Poon, T. H., Elliot, J. A. & Chung, C. A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials. Prostaglandins Leukot. Essent. Fatty Acids 89, 9–28 (2011).
13. Ras, R. T., Geleijnse, J. M. & Trautwein, E. A. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled trials. Brit. J. Nutr 112, 214–219 (2014).
14. Eussen, S. R., Blom, N. W., Sandvik, P. & van Eijkeren, J. C. Modelling approach to simulate reductions in LDL cholesterol levels after combined intake of stanols and phytosterols – stanols in humans. Lipids. Health. Dis 10, 187 (2011).
15. Kelly, E. R., Plat, J., Mensink, R. P. & Berendtschot, T. T. Effects of long term plant sterol and -stanol consumption on the retinal vasculature: a randomized controlled trial in statin users. Atherosclerosis 214, 225–230 (2011).
16. Scholle, J. M., Baker, W. L., Talati, R. & Coleman, C. I. The effect of adding plant sterols or stanols to statin therapy in hypercholesterolemic patients: systematic review and meta-analysis. J. Am. Coll. Nutr 28, 517–524 (2009).
17. Eussen, S. R. et al. Dose-dependent cholesterol-lowering effects of phytosterol/phytostanol-enriched margarine in statin users and statin non-users under free-living conditions. Public. Health. Nutr 14, 1823–1832 (2011).
18. Simons, L. A. Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. Am. J. Cardiol 90, 737–740 (2002).
19. Castro Cabezas, M., de Vries, J. H., Van Oostrom, A. J., Iestra, J. & van Staveren, W. A. Effects of a stanol-enriched diet on plasma cholesterol and triglycerides in patients treated with statins. J. Am. Diet Assoc 106, 1564–1569 (2006).
20. Richter, W. O., Geiss, H. C., Sönnichsen, A. C. & Schwandt, P. Treatment of severe hypercholesterolemia with a combination of beta-sitosterol and lovastatin. Eur. Cardiol 57, 497–505 (1996).
21. CATER, N. B., Garcia-Garcia, A. B., Vega, G. L. & Grundy, S. M. Responsiveness of plasma lipids and lipoproteins to plant stanol esters. Am. J. Cardiol 96, 23D–28D (2005).
22. Blan, S. N. et al. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am. J. Cardiol 86, 46–52 (2000).
23. De Jong, A. et al. Effects of plant sterol and stanol ester consumption on lipid metabolism, antioxidant status and markers of oxidative stress, endothelial function and low-grade inflammation in patients on current statin treatment. Eur. J. Clin. Nutr 62, 263–273 (2008).
24. Cylling, H. & Miettinen, T. A. Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolaemic non-insulin-dependent diabetic men. J. Lipid. Res 37, 1776–1785 (1996).
25. Goldberg, A. C. et al. Effect of plant stanol tablets on low-density lipoprotein cholesterol lowering in patients on statin drugs. Am. J. Cardiol 97, 376–379 (2006).
26. Fuentes, F. et al. Basal plasma concentrations of plant sterols can predict LDL-C response to sitostanol in patients with familial hypercholesterolemia. Eur. J. Clin. Nutr 62, 495–501 (2008).
27. Andrade, I., Santos, L. & Ramos, F. “Add-on” effect of phytosterols-enriched fermented milk on lipids and markers of cholesterol metabolism in statin-treated elderly patients. Steroids 99, 293–298 (2015).
28. Malina, D. M. et al. Additive effects of plant sterols supplementation in addition to different lipid-lowering regimens. J. Clin. Lipidol 9, 542–552 (2015).
29. Cheng, A. Y. & Leiter, L. A. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr. Opin Cardiol 21, 400–404 (2006).
30. Grundy, S. M. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227–239 (2004).
31. Kones, R. & Rumana, U. Current treatment of dyslipidemia: a new paradigm for statin drug use and the need for additional therapies. Drugs 75, 1187–1199 (2015).
32. Párraga-Martínez, L. et al. Long-term effects of plant stanols on the lipid profile of patients with hypercholesterolemia. A randomized clinical trial. Rev. Esp. Cardiol (Engl Ed) 68, 665–671 (2015).
33. Piironen, V., Lindsay, D. G., Miettinen, T. A., Toivo, J. & Lampi, A. M. Plant sterols: biosynthesis, biological function and their importance to human nutrition. J. Sci. Food. Agr 80, 939–966 (2000).
34. Plat, J. & Mensink, R. P. Plant stanol and sterol esters in the control of blood cholesterol levels: mechanism and safety aspects. Am. J. Cardiol 96, 15D–22D (2005).
35. Pouteau, E. B. et al. Non-esterified plant sterols solubilized in low fat milks inhibit cholesterol absorption—a stable isotope double-blind crossover study. Eur. J. Nutr 42, 154–164 (2003).
36. Cannon, C. P. et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med 372, 2387–2397 (2015).
37. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002).
38. Mozaffarian, D. et al. Population approaches to improve diet, physical activity, and smoking habits: a scientific statement from the American Heart Association. Circulation 126, 1514–1563 (2012).
39. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int. J. of Surg 8, 336–341 (2010).
40. Higgins, J. P. & Green, S. Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0. The Cochrane Collaboration. [Online] Internet: http://www.cochrane-handbook.org (accessed 25 May 2011).
41. Egger, M., Davey, S. G., Schneider, M. & Minder, C. Bias in meta-analyses detected by a simple, graphical test. BMJ 315, 629–634 (1997).

Acknowledgements
This study was supported by Nestec Limited (Nestlé R&D (China) Limited). The funding source had no role in the design or conduct of the study, collection, management, analysis, or interpretation of the data, or preparation, review, or approval of the manuscript.

Author Contributions
L.Q. and Y.Z. designed the study. S.H. conducted the study and wrote the main manuscript text. S.H., J.J. and J.X. analyzed the data and prepared all of figures. L.G., D.Z. and L.A.G. helped to interpret the results and revise the manuscript. All authors reviewed and approved the final manuscript. L.Q. and Y.Z. had primary responsibility for final content.

Additional Information
Competing financial interests: D. Zimmermann and L., Actis-Goretta, are employees of Nestlé Research Centre Lausanne. L. Guan and Y.Y. Zhao are employees of Nestlé Research Centre Beijing. The other authors declare that they have no competing financial interest.

How to cite this article: Han, S. et al. Effects of plant stanol or sterol-enriched diets on lipid profiles in patients treated with statins: systematic review and meta-analysis. Sci. Rep. 6, 31337; doi: 10.1038/srep31337 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016